Cytokinetics, Inc. (NASDAQ:CYTK) SVP Mark A. Schlossberg sold 10,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $23.07, for a total transaction of $230,700.00. Following the completion of the transaction, the senior vice president now directly owns 40,000 shares of the company’s stock, valued at approximately $922,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

CYTK opened at $22.67 on Friday. Cytokinetics, Inc. has a one year low of $7.72 and a one year high of $29.20. The company’s 50 day simple moving average is $24.04 and its 200-day simple moving average is $17.23.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.16). The firm had revenue of $3.83 million for the quarter, compared to analyst estimates of $4.92 million. As a group, equities analysts anticipate that Cytokinetics, Inc. will post -2.05 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in CYTK. Bessemer Group Inc. bought a new position in Cytokinetics in the first quarter valued at approximately $34,000. Victory Capital Management Inc. boosted its stake in Cytokinetics by 36.8% in the fourth quarter. Victory Capital Management Inc. now owns 11,371 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 3,057 shares during the last quarter. Virginia Retirement Systems ET AL bought a new position in Cytokinetics in the first quarter valued at approximately $126,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Cytokinetics by 35.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,690 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 1,477 shares during the last quarter. Finally, Sanders Morris Harris LLC bought a new position in Cytokinetics in the first quarter valued at approximately $145,000. 93.65% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on CYTK. HC Wainwright raised their price objective on shares of Cytokinetics from $38.00 to $59.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. BidaskClub lowered shares of Cytokinetics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 14th. Cantor Fitzgerald raised their price objective on shares of Cytokinetics from $29.00 to $41.00 and gave the stock an “overweight” rating in a report on Wednesday, July 15th. Raymond James began coverage on shares of Cytokinetics in a report on Friday, July 10th. They set a “strong-buy” rating and a $39.00 price objective for the company. Finally, JMP Securities raised their price objective on shares of Cytokinetics from $23.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $36.50.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Read More: What is the Quick Ratio?

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.